KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Income towards Common Stockholders: 2011-2025

Historic Net Income towards Common Stockholders for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Net Income towards Common Stockholders fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 131.95%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • Supernus Pharmaceuticals' Net Income towards Common Stockholders amounted to -$45.1 million in Q3 2025, which was down 300.53% from $22.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $38.5 million for Q3 2024, and its period low was -$45.1 million during Q3 2025.
  • For the 3-year period, Supernus Pharmaceuticals' Net Income towards Common Stockholders averaged around $3.7 million, with its median value being $1.2 million (2023).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Net Income towards Common Stockholders surged by 2,506.53% in 2024 and then tumbled by 9,641.13% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $2.4 million in 2021, then spiked by 943.45% to $25.5 million in 2022, then crashed by 95.39% to $1.2 million in 2023, then soared by 1,208.68% to $15.4 million in 2024, then slumped by 217.20% to -$45.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$45.1 million for Q3 2025, versus $22.5 million for Q2 2025 and -$11.8 million for Q1 2025.